Specifically, MSH6-negative status was found in 20% of signet-ring cell adenocarcinomas, 6.5% of mucinous adenocarcinomas, 0.8% of adenocarcinomas NOS, and 0% of neuroendocrine tumors (p = 0.001). Here, MSH6 is linked to signet ring cell carcinoma.